The ENRICH study examined BRII-179 as a priming therapy before administering elebsiran and PEG-IFNα.

Brii Bio announces positive end-of-treatment results from phase 2b ENRICH & ENHANCE studies to treat chronic hepatitis B: Durham, North Carolina Monday, July 6, 2026, 18:00 Hrs [I ...

DURHAM, N.C. and BEIJING, July 3, 2026 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a biotechnology company developing therapies to improve patient ...

In treatment-resistant chronic migraine, eptinezumab was associated with sustained reductions in headache burden.

Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia June 29, 2026 2:00 PM ...

End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses for functional cure ...

ITU AI for Good Global Summit 2026 opens Day Zero on July 7 at Palexpo Geneva, featuring agentic AI security workshops and ...

By letting presidents fire independent agency commissioners at will, the Supreme Court broke a deliberate diffusion of power that is as old as the Constitution itself.

The development of the 6G standard is entering a more concrete phase. At the June 2026 3GPP RAN Plenary in Singapore, the industry advanced several key areas under study and finalized the timeline for ...

Radiation therapy remains a central modality in cancer treatment, but normal-tissue toxicity and long-term stochastic effects ...

Objective Sarcopenia, defined by reductions in muscle mass and strength, increases the risk of adverse outcomes in patients with rheumatoid arthritis (RA)—driven in part by chronic inflammation—and is ...